Acute Lymphoblastic Leukemia
Specialty Channel

Featured Article
True or False: Due to increased toxicity and infection rates in older patients, dose intensification of induction treatment often is no justifiable option. Consequently, new treatment options are…
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.
Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.
Study findings being presented at the ASH Annual Meeting suggest blinatumomab as a new standard-of-care consolidation therapy before alloHSCT in young patients with high-risk first-relapse BCP-ALL.
True or False: Recent study results suggest chemotherapy-induced mutagenesis may be the source for relapse-inducing drug resistance mutations in patients with acute lymphoblastic leukemia.
True or False: Currently, the standard of care for central nervous system prophylaxis for pediatric high- or standard-risk B-cell acute lymphoblastic leukemia and no overt central nervous system…
True or False: The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukemia.
True or False: A positive pre-transplantation measurable residual disease was tied to a lower cumulative incidence of relapse for patients who underwent haploidentical stem-cell transplantation with…

News

Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.
Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.
Study findings being presented at the ASH Annual Meeting suggest blinatumomab as a new standard-of-care consolidation therapy before alloHSCT in young patients with high-risk first-relapse BCP-ALL.

Interactive Features

True or False: Due to increased toxicity and infection rates in older patients, dose intensification of induction treatment often is no justifiable option. Consequently, new treatment options are…
True or False: Recent study results suggest chemotherapy-induced mutagenesis may be the source for relapse-inducing drug resistance mutations in patients with acute lymphoblastic leukemia.
True or False: Currently, the standard of care for central nervous system prophylaxis for pediatric high- or standard-risk B-cell acute lymphoblastic leukemia and no overt central nervous system…
True or False: The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukemia.
Stay in the know.
OncNet Newsletter